BackChromocell Therapeutics Overview
Chromocell Therapeutics Corp.

Chromocell Therapeutics PEG Ratio

Chromocell Therapeutics (CHRO) has a PEG ratio of -0.01, above the sector sector average of -3.76.

Get informed when a big investor buys or sells

+ Follow

PEG Ratio

-0.01

PEG Ratio

-0.01

The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.

Average PEG Ratio (Comparison Companies)

Loading

PEG Ratio History

Loading

PEG Ratio Comparison

Loading

Chromocell Therapeutics (CHRO) FAQ

The latest PEG ratio for CHRO is -0.01. That is above the sector sector average of -3.76. Investors often review this figure alongside Chromocell Therapeutics's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, CHRO currently prints -0.01 for PEG ratio, while the sector average sits near -3.76. That is roughly 99.7% above the sector mean. Large gaps often invite a closer look at Chromocell Therapeutics's growth, margins, and balance sheet.

A PEG ratio of -0.01 for Chromocell Therapeutics is not 'good' or 'bad' on its own. Compare it with the peer average (-3.76) and with CHRO's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting CHRO's PEG ratio (-0.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.